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Abstract
Multiple sclerosis (MS) is a complex multifactorial disease of the central nervous system (CNS) for which animal models have
mainly addressed downstream immunopathology but not potential inducers of autoimmunity. In the absence of a
pathogen known to cause neuroinflammation in MS, Mycobacterial lysate is commonly used in the form of complete
Freund’s adjuvant to induce autoimmunity to myelin proteins in Experimental Allergic Encephalomyelitis (EAE), an animal
model for MS. The present study demonstrates that a protein from the human endogenous retrovirus HERV-W family
(MSRV-Env) can be used instead of mycobacterial lysate to induce autoimmunity and EAE in mice injected with MOG, with
typical anti-myelin response and CNS lesions normally seen in this model. MSRV-Env was shown to induce proinflammatory
response in human macrophage cells through TLR4 activation pathway. The present results demonstrate a similar activation
of murine dendritic cells and show the ability of MSRV-Env to trigger EAE in mice. In previous studies, MSRV-Env protein was
reproducibly detected in MS brain lesions within microglia and perivascular macrophages. The present results are therefore
likely to provide a model for MS, in which the upstream adjuvant triggering neuroinflammation is the one detected in MS
active lesions. This model now allows pre-clinical studies with therapeutic agents targeting this endogenous retroviral
protein in MS.
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Introduction
Multiple sclerosis is a complex multifactorial disease of the
central nervous system, which involves environmental factors
and genetic susceptibility as upstream factors [1]. As these
aetiological factors have not yet been clearly defined, MS studies
have predominantly been focused on the resulting pathogenic
process involving neuroinflammation, demyelination, axonal
damage and defects in myelin repair [2,3,4]. Animal models for
MS have also been dedicated to the study of downstream
effectors of anti-myelin autoimmunity and neuroinflammation
thus developing experimental allergic encephalomyelitis (EAE)
as the unique model for pre-clinical therapeutic assessment for
MS [5,6]. As no ‘‘upstream’’ pathogen responsible for the
induction of demyelinating neuroinflammatory lesions of MS
had been identified, a ‘‘heterologous’’ pathogen extract, i.e.
mycobacterial lysate with peculiar immunoadjuvant properties
capable of promoting auto-immunity against artificially pre-
sented myelin antigens, has been used in the form of mineral oil
suspension designated as ‘complete Freund’s adjuvant’ -CFA-
[7,8]. This has permitted the elucidation of many immunolog-
ical functions that could lead to immune-mediated demyelin-
ation and, consequently, has delineated the therapeutic scope
for MS within the boundaries of immunological effectors
[9,10,11].
Following the discovery of retroviral RNA sequences from
Multiple Sclerosis associated RetroViral element (MSRV) in virion
particles associated with reverse-trancriptase activity from MS cell
cultures [12,13], a previously unknown family of human
endogenous retroviruses (HERV) was identified (HERV-W) [14].
Families of ‘‘endogenous’’ retroviruses refer to what is now known
to represent 8% of the human genome and to result from ancestral
retroviral infections that have integrated proviral genomes in
chromosomes of germ-line cells [15]. These retroviral sequences
are part of the human genome but have an uneven distribution in
the population [16,17,18]. Although the great majority of them
are inactivated by genetic alterations and the few potentially active
elements with open reading frames (orf) are usually epigenetically
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silenced, non-physiological expression of retroviral genes and
particles have been reported in several human diseases [19].
Concerning the HERV-W family and its virion-associated
MSRV element, an association with multiple sclerosis has been
repeatedly and independently demonstrated over the past two
decades [12,18,20,21,22,23,24,25,26,27].
Moreover, as the expression of HERV-W elements in MS could
have been a consequence of the disease process without
pathogenic effect, studies have addressed the potential pathoge-
nicity of MSRV particles and of corresponding proteins on
immune and glial cells. Those studies have shown a pathogenic
effect on glial cells [28] and the resulting cellular effects impairing
remyelination have only been recently elucidated [29]. Most
importantly, they have also shown a potent immunopathogenic
effect of MSRV virions caused by the envelope protein (MSRV-
Env) on T-lymphocytes [30] with a predominant upstream
activation of innate immunity specifically mediated by the TLR4
receptor and its CD14 co-receptor [31]. These results have
consequently made it obvious that this HERV-W expression
producing MSRV particles and/or proteins would not be neutral
to surrounding cells and could play a role in the MS pathogenic
process.
Data from successive and independent studies showed the
presence of HERV-W/MSRV-Env protein (using detection
antibodies specific for highly conserved HERV-W Env proteins)
on macrophages or microglial cells in active plaques of all MS
brains studied to date [20,25,26,32]. This has led to the hypothesis
that MSRV-Env expression may be pivotal in the initiation of
pathogenic process leading to MS lesions.
In order to further explore this possibility, we have evaluated
whether MSRV-Env protein could trigger EAE development in
mice if used instead of mycobacterial lysate of Complete Freund’s
adjuvant. The protein was expressed either from the full-length
open reading frame (orf) of an MSRV-env clone or from a
truncated portion of the protein comprising its surface domain
(SU) containing the TLR4-stimulating region. The present study
demonstrates that MSRV-Env protein from the HERV-W family
is efficient in inducing EAE in C57/BL6 mice when administered
in emulsion together with myelin oligodendrocyte glycoprotein
(MOG) peptide 35–55. MSRV-Env-induced disease developed
with clinical and histopathological features indistinguishable from
those of standard EAE. These results support an in vivo
pathogenicity of this peculiar HERV-W protein and suggest that
it may play a similar pathogenic role in MS.
Materials and Methods
All animal work has been conducted according to relevant
national and international guidelines. The protocol was approved
by the Committee on the Ethics of Animal Experiments of Lyon-1
University (Permit Number: BH2009-09)and all efforts were made
to minimize suffering.’’
Proteins and toxins
Recombinant Env protein was produced for Geneuro by
Protein’Expert (Grenoble, France) from plasmid pV14 [30]
encompassing the complete orf of HERV-W envelope protein
(58 KDa, 542 aminoacids) cloned from MSRV virion RNA (Env;
GenBank no. AF331500.1). Env-SU is a 33-kDa and 293 amino
acids fractions of the full-length MSRV-Envelope protein (542
amino acids). The recombinant Env-SU protein was produced and
purified by Protein’eXpert (Grenoble, France) as previously
described (Rolland et al. 2006). The proteins were refolded and
biologically active. As a negative control, a mock protein was
synthesized and purified under the same conditions. Fifty-
microgram aliquots per -milliliter were flash frozen into liquid
nitrogen and then stored at 280uC. Quality and purity of the
recombinant proteins were assessed by mass spectroscopy and
western-blot. The presence of endotoxins in proteins preparations
was tested by a Limulus -amebocyte -lysate (LAL) test performed by
CleanCells (Bouffere, France), and all production batches were
below the detection level of 5 UI/ml.
Details on env protein sequence, domains and productions are
also provided in Figure S22 and QC reports in File S1.
Mouse mAb specific for HERV.W proteins were provided by
GeNeuro SA (Geneva, Switzerland): GN-mAb_03 is targeted
against Env-SU protein and GN-mAb12 against gag protein.
Myelin Oligodendrocyte Glycoprotein (MOG) peptide MOG 35–
55 was obtained from (Enzo Life Science AG, Lausanne,
Switzerland) and Bordetella pertussis toxin from (Sigma-Aldrich,
France).
Mice
For Env-SU series, pathogen-free 6 week-old wild-type C57BL/
6 mice were purchased from Janvier (France). TLR4 knockout
(KO) mice and CD14 KO mice were obtained from Dr. Bernard
Ryffel from the Centre National de la Recherche Scientifique/
Centre de Distribution, Typage et Archivage Animal (CNRS,
Orle´ans, France). For replication series with entire Env protein, as
presented here, 10 weeks old C57BL/6 mice were purchased from
Taconic Farms, USA.
DC culture and stimulation
DC were generated from bone marrow (BM) as described
(Berthier et al., 2000). Briefly, BM cells were isolated by flushing
cells from the femurs. Erythrocyte and Gr1+ cells were removed by
magnetic cell sorting. Negatively selected cells were resuspended at
56105 cells/ml in complete Iscove’s modified Dulbecco’s medium
(IMDM) (Gibco, Invitrogen, Grand Island, NY, USA) supple-
mented with 1% of -GM-CSF-transfected J558 cell line superna-
tant, 40 ng/ml of mouse recombinant FLT-3L, and 5 ng/ml of
mouse recombinant IL-6. Every 3 days, cells were resuspended at
56105 cells/ml in complete IMDM. By day 6, IL-6 was removed
and FLT-3L was used at 20 ng/ml. BM-DC were plated in 24-
well plates at a concentration of 16106/well in 1 ml of culture
medium after stimulation with LPS and different amounts of Env-
SU: cells were incubated at 37uC in 5% CO2 in humidified
atmosphere for 24 h. For inhibition experiments with mAb, 1 mg
of Env-SU and LPS was preincubated for 45 min at 4uC with
30 mg/ml of GN-mAb_03 anti Env mAb or of GN-mAb_12 anti
gag mAb as control prior addition to DC culture.
Cellular analysis
For flow cytometry analysis, cells were harvested, washed in
PBS, 3% FCS, 0.16% sodium azide and immunostained for
surface expression of distinct markers for 30 min at 4uC. The
conjugated Ab used for staining were all obtained from BD
Biosciences: IAB-PE, CD11c-APC. Data acquisition and analysis
were performed with a FACS Aria flow cytometer and the
software FACSDiva5 (BD Biosciences). A propidium iodide
staining has been done in order to exclude dead cells.
Cytokine production assays
Culture supernatants were collected and concentrations of the
proinflammatory cytokines IL-6, IL-12p70, cIFN, and TNF-a
were measured using ELISA kits (BD Pharmingen, eBioscience),
according to manufacturer’s instructions.
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EAE induction in mice
C57BL/6 female mice (6–8 weeks of age) were acclimated in the
animal facility for two weeks and were immunized (day 0)
subcutaneously at 2 sites of the neck and in the flanks (day 7 and
day 14) with 200 mg of MOG 35–55 (NeoMPS, Strasbourg) per
animal either 1) emulsified in complete Freund’s adjuvant (CFA)
containing 400 mg of Mycobacterium tuberculosis H37RA (DIFCO
Laboratories, Detroit, MI), or 2) in incomplete Freund’s aduvant
(IFA) an emulsion containing various quantities (10 mg to 50 mg) of
MSRV-Env, either as complete protein or as Env-SU part, or 3) in
IFA alone. Immediately thereafter the mice received an intraper-
itoneal injection of Bordetella pertussis toxin (550 ng of in 0.1 mL of
PBS per mouse). Mice were examined daily for at least 30 days for
disability. Clinical scores were defined as follows: 0, no signs; 1,
loss of tail tonicity or hyper-reflexia of hindlimb(s) or unilateral
hindlimb weakness; 2, bilateral hindlimb or forelimb weakness; 3,
plus unilateral paralysis or major deficit; 4, complete hindlimb or
forelimb paralysis; 5, plus partial paralysis or major deficit of
opposite limbs; 6, moribund or death. EAE induction experiments
were consistently repeated in animal facilities of Lyon 1 University,
Grenoble University and Hooke Laboratories in Lawrence (MA),
following respective animal experimentation regulation with
approval of local ethic committees for animal research.
Histological analysis
At the termination of the experiment, spinal cords and brains
were collected from two mice treated by Env protein which had
developed clear signs of EAE (mice 1-1 and 1-2) and from one
mouse which had significant weight loss during the first 2 weeks
after immunization, but which never developed clinically detect-
able paralysis (mouse 2–5). Histological analysis was performed on
these tissues.
After the mice were euthanized and perfused with PBS, the
spinal cords and heads were collected into buffered formalin. For
each mouse, 9 to 12 Luxol fast blue stained sections and 9 to 12
hematoxylin and eosin (H&E) stained sections, from lumbar,
thoracic, and cervical spinal cord, were prepared and analyzed (3
to 4 sections from each region of the spinal cord). In addition, 3
Luxol fast blue stained sections and 3 H&E stained sections, from
medulla oblongata, hind part of cerebellum, and rostral part of
cerebellum, were prepared and analyzed from mice 1-1 and 1–2 (1
section from each region of the brain). Histological analysis was
performed blind by a pathologist who was not aware of the clinical
scores of the mice.
Information on microscope image acquisition. Make
and model of microscope: Zeiss Imager A1; Type, magnification,
and numerical aperture of the objective lenses: Zeiss Plan-
NEOFLUAR 56/0.16 Zeiss Plan-NEOFLUAR 406/0.75; Im-
aging medium: air; Camera make and model: Zeiss AxioCam ERc
5s (with 0.5 adapter); Acquisition software: Zeiss AxioVision.
Count of inflammatory foci. Inflammatory foci of approx-
imately 20 cells were counted in each H&E stained section. When
inflammatory infiltrates consisted of more than 20 cells, an
estimate was made of how many foci of 20 cells were present.
Estimation of demyelination. The demyelination score
represents an estimate of the demyelinated area for each section
as follows:
0 – no demyelination (less than 5% demyelinated area); 1–5 to
20% demyelinated area; 2–20 to 40% demyelinated area; 3–40 to
60% demyelinated area; 4–60 to 80% demyelinated area; 5–80 to
100% demyelinated area
For Luxol fast blue stained slides, the size of the demyelinated
area was estimated based on less intense blue staining of myelin.
For H&E stained sections, the demyelinated area was estimated
by looking for interruption of normal structure – pallor and
vacuolation consistent with edema and demyelination, and dilated
axons.
Count of apoptotic cells. The number of apoptotic cells in
the H&E sections was determined.
Myelin auto-antigen recall
At the end of the study period (day 30), mice from Env-SU
series with clinical signs of EAE and controls were injected i.p.
with 200 mg of MOG 35–55. Three days later, mice were
sacrificed and spleen collected. Suspension of spleen cells were
cultured for 24 h, 48 h and 72 h at 26106 cells/ml in RPMI 1640
(Invitrogen: Gibco 72400) supplemented with 20% FCS with or
without addition of MOG (1 mg, 5 mg, 10 mg and 20 mg). In total,
5 independent culture experiments were performed, employing a
total of 3 IFA mice and 6 Env mice.
Results
In order to analyze the effects of the MSRV-Envelope protein
under similar conditions to our previous study [31], we initially
used the same surface subunit (Env-SU) that contains the TLR4-
activating site. Thereafter, the entire envelope protein (Env) was
used for a series of EAE studies in which detailed histological
analysis was performed.
MSRV-Env induced surface expression of dendritic cell
maturation markers
To determine whether MSRV-Env-SU stimulated phenotypic
changes associated with dendritic cell (DC) maturation, flow
cytometry analyses were performed for the expression of CD11c
and MHC class II (MHCII) by primary DC derived from bone
marrow of mice. The CD11c marker is found on immature and
mature DC and the MHCII molecules expression increase
specifically on mature DC. Immature DC were treated with
2 mg/mL Env-SU, 2 mg/mL LipoPolySaccharide (LPS, a TLR4
pathway activator), or 20 mg/mL PSB (Pansorbin, a TLR2
pathway activator). After 24 h of incubation, DC maturation
was measured by flow cytometry analysis for MHCII expression
among CD11c positive cells (Figure 1). The proportion of double
positives cells (MHCII+, CD11c+) among LPS or MSRV-Env-SU
stimulated DC was strongly increased (68.1% and 65.8%,
respectively) compared to unstimulated DC (33%). At the same
time, there was a decrease in the number of CD11c+, MHCII2
cells (49.9% in unstimulated versus 27.5% and 24.6% in stimulated
DC), indicating that DC differentiated to mature state. These
results show that Env-SU, similar to LPS, can efficiently induce
phenotypic maturation of DC from mice.
MSRV-Env stimulates the production of pro-inflammatory
cytokines in murine DC cultures
To analyse pro-inflammatory cytokine production, we harvested
and stimulated C57BL/6 DC with increasing concentrations of
Env-SU for 24 h. Secretions of IL-6, TNFa and IL-12p70 in cell
culture supernatants were analysed by ELISA (Figure 2). LPS
stimulation was used as the reference for the TLR4 pathway
activation. We observed that Env-SU induced the production of
the pro-inflammatory cytokine IL-6 in a dose dependent manner,
similarly to LPS (Figure 2A). In addition, IL-12p70 (Figure 2B)
and TNFa (Figure 2C) production was also increased in a dose
dependant manner, similarly to the production induced by LPS.
To assess the specificity of Env-SU pro-inflammatory proper-
ties, we studied the effects of anti-Env monoclonal antibodies
Human Retroviral Protein Promotes EAE
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Figure 1. Env-SU induces the maturation of murine DC. DC from wild-type C57Bl/6 mice were stimulated with LPS (2 mg/mL) or Env-SU (2 mg/
mL). After 24 h of incubation, cells were analysed by cytofluorometry for MHC class II and CD11c surface markers expression. DC were harvested,
washed in PBS with 3% FCS and 0.16% sodium azide and immunostained for MHCII (monoclonal IAb-PE antibody) and for CD11c (monoclonal CD11c-
APC antibody) for 30 min at 4uC. The conjugated Abs used for staining were all obtained from BD Biosciences. A propidium iodide staining has been
used to exclude dead cells. Double positive cells for CD11c and MHC-II (upper right quadrant) represents mature DC. Upper panel: Graphic
distribution of cells according to immunostaining intensity for CD11c (abscissa) and MHCII (ordinate) without stimulation (left), after stimulation by
LPS (center) or after stimulation by MSRV-Env (right). Lower panel: Corresponding percentage of cells in each quadrant, below each graphic. Results
are representative for three experiments.
doi:10.1371/journal.pone.0080128.g001
Figure 2. Env-SU induced the production of pro-inflammatory cytokine in DC culture. Murine Bone marrow DC were stimulated with LPS
(2 mg/mL), PSB (100 mg/mL) and different amounts of Env-SU for 24 h. Culture supernatants were then analysed by ELISA for IL-6 (A), TNFa (B) and IL-
12p70 (C) production. In (D), the specific inhibition of MSRV-Env stimulated DC by anti-Env neutralizing monoclonal antibody (GN-mAb_03) is shown,
compared to an irrelevant anti-MSRV Gag (GN-mAb_12) or to diluents without antibody. IL-6 levels obtained in non-stimulated DC (medium) as
negative control, or stimulated with LPS as positive control are also shown. IL-6 production was measured by ELISA in supernatants after 24 h of
incubation (ELISA standard deviations ,5%). These results are representative of three experiments realised under identical conditions.
doi:10.1371/journal.pone.0080128.g002
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(mAb) on the cytokine production (Figure 2D). We used a mAb
targeting specific Env epitope, which was shown to neutralize Env-
SU effects in human PBMC [31]. DC were incubated for 24 hours
with Env-SU or LPS in the presence of mAb. DC showed a
significant decrease of IL-6 production when our mAb was added
in Env-SU stimulation, compared to DC incubated without mAb.
No effect of this mAb was observed in LPS stimulation. IL-6
secretion was not affected in either case by treatment with an
irrelevant control mAb specific for HERV-W Gag antigen
(expressed from an MSRV clone).
In conclusion, our data demonstrate that MSRV-Env-SU
induces the production of pro-inflammatory cytokines in a specific
manner by C57Bl/6 DC that correlate with previous findings in
human PBMC and DC (Rolland et al., 2006).
Cytokine production by TLR4-KO and CD14-KO DC in
response to MSRV-Env
DC are professional antigen presenting cells expressing a variety
of Toll-like receptors (TLR). TLR are essential in host defence
against pathogens due to their capacity to detect microbes and
initiate the innate immune response. We previously showed that
TLR4/CD14 is triggered by MSRV-Env in human PBMC and
DC (Rolland et al., 2006). Therefore, we checked whether this
pathway is also engaged by this HERV agonist in mouse DC using
TLR4 Knock Out (KO) and CD14 KO mice as the source of cells
(Figure 3). LPS-induced production of IL-6 was significantly
decreased in TLR4-KO mice compared to wild-type mice,
whereas IL-6 production induced by pansorbin (PSB), targeting
TLR2, remained the same for DC of both mice (Figure3A).
Similar results were observed for CD14-KO mice DC although
IL-6 secretion was less decreased in CD14-KO mice than in
TLR4-KO mice, which can be explained by only partial
dependency of LPS activation on CD14 (Figure 3B). These results
confirmed that the TLR4 pathway of DC from TLR4-KO mice
was functionnaly impaired in TLR4-KO mice and that the TLR2
pathway, induced by PSB, was still functioning as expected. As
Env-SU failed to activate DC derived from either TLR4-KO or
CD14-KO mice, MSRV-Env stimulation of murine DC was
shown to depend on the TLR4 pathway in which the co-receptor
CD14 participates as an accessory molecule.
Immunization with MOG in presence of MSRV-Env
induces EAE symptoms in C57Bl/6
Experimental allergic encephalitis (EAE), the mouse model for
MS, experimentally addresses the pathogenesis of the central
nervous system injury following an autoimmune response (CNS).
In order to study the potential role MSRV-Env may play in vivo,
C57Bl/6 mice were immunized with myelin peptide MOG35–55
emulsified with either the complete Freund’s adjuvant (CFA) or
MSRV-Env-SU in incomplete Freund’s adjuvant (IFA). In
addition, as classically used in EAE for its ability to trigger the
disruption of the blood brain barrier, Bordetella Pertussis Toxin
Figure 3. Comparison of IL6 production in Env-SU stimulated murine DC derived from TLR4 KO and CD14 KO mice compared with
wild-type mice. IL-6 production in bone marrow DC culture supernatants of TLR4 KO (A) and CD14 KO (B) mice compared to wild-type C57BL/6
mice after 24 h of stimulation with LPS, PSB and graded dose of Env-SU. Percentages shown in the histogram correspond to the percentage of
residual IL6 secretions dosed in cells supernatants of TLR4 or CD14 KO mice relative to wild-type mice. Data presented are representative of three
experiments under identical conditions.
doi:10.1371/journal.pone.0080128.g003
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(PTX) was injected as indicated in Material and Methods. Figure 4
shows the clinical scores of two different experiments (representing
repeatedly obtained experimental series with Env-SU; n.3)
between day 0 and day 30. Table I indicates the disease incidence
and the mean clinical scores of the different groups (IFA, CFA, Env-
SU 10 or 50 mg) of injected mice at different days. The scores
represent the means of animals in each group. A period of latency
between seven to ten days was noticed after immunization, followed
by a progressive increase in the clinical score from day 10 to day 30 -
in both Env-SU and CFA treatedmice (Figure 4A&B). Moreover, as
clinical scores were higher in the group injected with 50 mg than
with 10 mg of Env-SU, the response appeared dose-dependent.
Similar experiments of EAE induction were performed with the
full-length MSRV-Env protein in C57/BL6 mice, as its synthesis
Figure 4. MSRV induced EAE like symptoms in C57Bl/6 mice. Experiments were performed on 6–8 weeks-old C57BL/6 female mice. Mice were
immunized subcutaneously with 200 mg of MOG 35–55 per animal emulsified in CFA containing 400 mg of Mycobacterium tuberculosis H37RA, or an
emulsion containing 10 mg or 50 mg of Env-SU in IFA, or an emulsion containing 20 mg or 50 mg of full-length Env protein (in C), or MOG with IFA
alone. Immediately thereafter and again 2 days later, the mice received an intraperitoneal injection of 200 ng of Bordetella pertussis toxin in PBS. Mice
of IFA, CFA or Env groups were examined daily and clinical score were then monitored on the clinical scale of 0 to 6. Mean scores and standard
deviation (A–B) or SEM (C) for each group of mice are presented. The values are representative for three experiments with Env-SU and more than
three with full-length MSRV-Env (with protocol variants) that repeatedly showed similar induction of EAE.
doi:10.1371/journal.pone.0080128.g004
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and purification became available (Cf. Figure S2, S3 in File S1)
and because multiple epitopes compatible with full-length Env
protein have been detected in MS brain lesions [26]. MOG-EAE
induction with the full-length Env protein in C57/BL6 mice was
also reproduced in a reference laboratory (Hook laboratories, MA,
USA) as presented here with two doses (20 mg and 50 mg) over a
49 days study period (Figure 4C).
As illustrated in Figure 4C no mice showed signs of paralysis up
to Day 21, which appears to be a longer delay that what was
generally observed with Env-SU. Between Days 22–31 (50 mg) or
22–33 (20 mg) mild signs of paralysis appeared in several mice. On
Days 31–33 (50 mg) and 34–37 (20 mg), mice showed clear onset of
paralysis that was indistinguishable from paralysis which develops
in standard MOG35–55-induced EAE (Figure 4C). The disease
progressed further, and by Day 49, 5 of 6 mice (50 mg) and 6 of 6
mice (20 mg) had developed EAE. The mean maximum score
(MMS), the mean day of onset and the weight gain at the
termination of the study (in %, relative to the weight measured on
Day-1), are presented in Table II. Statistical analyses are also
presented in Table II and confirm the significant differences
between the control group (IFA+MOG) and the mice injected with
Env. Interestingly, with similar numbers tested in this experiment
(n = 6) the MMS value becomes significantly different from the
control group in mice injected with 50 mg of Env protein (p,0.01),
whereas it is at the limit of significance (p= 0.58) in mice injected
with 20 mg. This indicates a dose-dependent effect on the
neurological symptoms, whereas the impact on the weight kinetics
appears similar with the two MSRV-Env doses.
Altogether, these data demonstrate that immunization with
MOG35–55, together with either Env-SU or entire Env protein of
MSRV is able to induce in vivo neuropathological inflammation
indistinguishable from classic EAE.
Histological analysis
Histological analysis confirmed the clinical data of MSRV-Env
induced EAE. Mice 1-1 and 1-2 with MMS of 3.5 and respective
clinical scores of 2.5 and 3.5 at the end of the study were examined
(Table I, and details in section II of File S1). Analysis was
performed on 3 regions of the spinal cord and 3 regions of the
brain. Between 4 and 7 inflammatory foci were found in each
analyzed section of the spinal cords of both mice (Figure 5A, C–D).
Mild to moderate demyelination (scores 1 to 3) was found in each
analyzed section of the spinal cord stained with Luxol fast blue
(Figure 5B). Demyelination scores were similar for the H&E and
Luxol fast blue stained sections. Between 1 and 5 apoptotic cells
were found in each analyzed section of the spinal cord (Cf. Table
S5 in File S1). This is similar to what is seen in standard MOG35–
55/CFA-induced EAE and is not observed in IFA controls (data
not shown).
Demyelination is considered difficult to estimate in brain
sections of mice with EAE, demyelination levels are usually not
assessed in brains of mice with standard MOG35–55-induced
EAE. Since this MSRV-Env model is novel, an attempt was
nonetheless made to estimate the demyelination in the brain
sections. Between 3 and 8 inflammatory foci were found in each
analyzed section for both mice. In the Luxol fast blue stained
sections, demyelination score was 1 to 3 in areas of inflammation.
In H&E stained sections we estimated the percent of inflamed
areas with interruption of normal structure, with pallor and
vacuolation consistent with edema and demyelination (Cf. Figures
S10 to S21 in File S1). Apoptotic cells were also found in 4 of 6 of
these sections (4 to 9 apoptotic cells/section).
Inflammatory infiltrates consisted predominantly of mononu-
clear cells. Demyelination was detected in both H&E and Luxol
fast blue stained sections. The number of inflammatory foci, the
number of apoptotic cells and the severity of demyelination were
consistent with the clinical scores (for detailed Tables, see section
II and annexed raw data of File S1).
Such histological aspects of the lesions in the spinal cords and
brains of Env-induced EAE mice were not different from the
findings typical of standard EAE. In addition, brain lesions with
marked demyelination were readily detectable in MSRV-Env
induced EAE.
Similar histological analysis was performed on an additional
case, mouse 2–5, which had significant weight loss during the first
2 weeks after immunization but which did not develop clinically
detectable paralysis during the study period, in order to address
potential lesions in a sub-clinical phase of EAE.
Three regions of the spinal cord were analyzed in parallel with
the above described mice 1-1and 1-2 (Figure 5), and 3 sections
from each region were prepared and scored. Mouse 2–5 had
inflammatory foci in all 3 sections of the lumbar region (1 to 2
inflammatory foci/section), but none in the thoracic or cervical
regions. Apoptotic cells were found in 16 out of the 18 sections
examined from mice 1-1 and 1-2, but none were found in the 9
sections examined from mouse 2–5 (details in section II of File S1).
These finding are consistent with a mild inflammation of the
spinal cord in that could explain the absence of clinically
detectable signs despite an ongoing lesion process in several
animals of our EAE group.
MOG recall of immunized mice leads to cIFN production
In order to investigate a specific immune response toward the
MOG35–55 antigen, splenocytes were harvested from MOG35–
55/IFA or MOG35–55/Env-SU immunized mice, three days
after recall injection of MOG on day 30 (Cf. Materials and
Methods). Cultured T lymphocytes from spleen of MOG35–55/
Env-SU immunized mice responded to MOG35–55 challenge
Table 1. Immunisation with MOG and MSRV-Env-SU induces dose-dependent EAE-like symptoms in C57BL/6 mice.
Group Treatment disease mean disease mean score max score mean cumulative
incidence (nb) onset (d) d30 score d30
IFA 0/4 - 0 0 0
CFA 5/5 12,2 1,4 1,8 31,2
ENV 50 mg 7/7 9,1 1,9 2,9 56,9
ENV 10 mg 7/7 14,6 0,4 1,6 18,7
Data correspond to those illustrated in figure 4A. Disease incidence, mean time to disease onset, mean clinical score at day 30, mean maximum score and mean
cumulative score at day 30 were calculated for each group of mice.
doi:10.1371/journal.pone.0080128.t001
Human Retroviral Protein Promotes EAE
PLOS ONE | www.plosone.org 7 December 2013 | Volume 8 | Issue 12 | e80128
with a significant secretion of cIFN, which was not observed in the
cultured splenocytes from MOG35–55/IFA immunized control
animals (Figure 6A). T cells from Env-SU treated mice produced
significant amounts of cIFN in a dose dependent manner to reach
a maximum at 10 mg/mL of MOG35–55. Kinetic analysis of the
anti-MOG T-cell response showed significantly elevated cIFN
productions at 24 h (800 pg/mL), 48 h (1800 pg/mL) and 72 h
(4200 pg/mL) in Env-SU mice when compared to -IFA treated
control mice (Figure 6B).
These results ascertain that the combination of MOG35–55
antigen with MSRV-Env-SU, is able to promote specific
autoimmune response towards this antigen with the characteristics
of a Th1 polarisation of T lymphocytes similar to the features of
classic EAE.
Discussion
The envelope protein expressed by a retroviral element of the
HERV-W family, MSRV [12], was previously shown to display
potent pro-inflammatory activity either when associated with
virion particles, or as a full-length protein (MSRV-Env), or as the
fragment encompassing its surface subunit (Env-SU) [30,31].
Previous studies have shown that MSRV particles exert potent
pro-inflammatory effects in vitro, in human PBMC and DC
(Rolland et al., 2006) as well as in vivo, in humanized SCID mouse
model grafted with human lymphoid cells, in which injected
MSRV virions caused an overexpression of TNF-a leading to
death by brain haemorrhages [30,33]. Furthermore, MSRV-Env-
SU was found to provoke this inflammatory reaction through
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Figure 5. Histological analysis of cervical spinal cord (mouse
#1-1). A. Microscopic changes in transverse section of spinal cord are
shown (1006). Multiple inflammatory foci and some multifocal
inflammatory lesions are present in the leptomeninges, around blood
vessels in the leptomeninges and white matter, and parenchyma of the
white matter (arrows). There is also vacuolation in the white matter that
is consistent with edema and demyelination. B. Luxol fast blue stained
section of cervical spinal cord (1006). This section is from the same
block of tissue as the H&E stained section shown in A. Areas of
demyelination are visible within white matter (lighter blue stained
areas, in the outer parts of the spinal cord; arrows). C. H&E stained
transverse section of thoracic spinal cord (1006). Four multifocal
inflammatory lesions are present in the leptomeninges, around blood
vessels in the leptomeninges and white matter (box and arrows). There
also is vacuolation in the white matter that is consistent with edema
and demyelination (box). D. H&E stained section of thoracic spinal cord
(4006). Detail of the above slide (boxed area). Two multifocal
inflammatory lesions are shown (arrows).
doi:10.1371/journal.pone.0080128.g005
Human Retroviral Protein Promotes EAE
PLOS ONE | www.plosone.org 8 December 2013 | Volume 8 | Issue 12 | e80128
engagement of the TLR4/CD14 pathway [31]. The present study
reveals that MSRV-Env is also able to activate cells of the innate
immune system in mice leading to proinflammatory cytokine
productions through pattern recognition receptors TLR4 and
CD14. Furthermore, when associated with MOG antigen, specific
immune response of T cells producing c-interferon is mounted.
These combined innate and specific acquired immune responses
lead to the development of neuropathology similar to standard
EAE.
TLR constitutes a large family of receptors which is character-
ized, among other features, by the nature of their ligands. TLR are
expressed in mammalian immune cell types such as B cells [34],
macrophages, monocytes, dendritic cells [35], oligodendrocytes
[36], astrocytes [37], microglia [38] and neurons [39]. TLR can
sense distinct microbial products and are central to innate immune
response to various classes of pathogens [40,41]. Among viruses
known to activate TLR, an endogenous retrovirus such as Mouse
Mammary Tumor Virus (MMTV) has been found to mediate
activation and cellular maturation of murine DC in vitro and in vivo
by direct interaction with TLR4 [42]. Moreover, specific
activation of CNS innate immunity through TLR4 can lead to
neurodegenerative processes via activation of brain-resident
macrophages [43] and TLR4 is necessary for LPS-induced
oligodendrocyte injury in the CNS [44]. These results indicate
that the engagement of TLR4 receptor expressed on CNS
resident, and/or perivascular, macrophages by its ligands can
contribute to oligodendrocyte damage and neurodegeneration.
By inducing the production of proinflammatory cytokines by
murine immune cells via CD14 and TLR4 pathway, MSRV-
Env can thus cause neuroinflammation and brain damage. Its
presence in MS plaques also suggested that MSRV-Env is a
relevant candidate capable of causing the immunopathogenic
features of human neuroinflammatory diseases such as MS
[26]. The pro-inflammatory effects of MSRV-Env have been
shown to result from TLR4 and CD14 receptor pathway
activation, because TLR4 blockade strongly inhibited the
induction of the T-cell specific cytokine (cIFN) by MSRV-
Env protein, in human PBMC cultures [31]. In the present
study, we showed that MSRV-Env activation of DC is
completely abrogated in mice deficient for either TLR4 or
CD14. Thus, the pro-inflammatory properties of MSRV-Env
protein from HERV-W appear to involve the activation
cascades initiated by the engagement of CD14 and TLR4 in
human and mouse cells as well.
In the central nervous system, TLR are expressed on different
cell types and can influence local immune responses. For example,
there is a marked increase in the expression of TLR within MS
brain lesions or cerebrospinal fluid mononuclear cells, as well as
within demyelinated lesions of EAE [36]. Thus, EAE has proven
invaluable in understanding distinct clinical and pathological
features of MS [45,46,47]. In the present study, we have therefore
addressed the potential of MSRV-Env protein to trigger the
development of EAE. Our data demonstrate that mice injected
with MSRV-Env in the presence of MOG 35–55 peptide clearly
developed EAE. Demyelinating neuroinflammation in the CNS
was confirmed by neurohistological analysis. In addition, signifi-
cant inflammatory and autoimmune responses against the
MOG35–55 peptide were revealed. The body weight changes
suggest that this new model of EAE may be remitting-relapsing,
with the first wave of EAE being subclinical. Similar clinical
Figure 6. EAE mice induced by Env-SU display anti-MOG autoimmunity in splenocytes cultures. A. cIFN secretion of pooled splenocytes
(2 mice for the IFA group and 3 mice for the Env-SU group) of EAE mice assessed by ELISA of culture supernatants 24 h after stimulation. B. Kinetics of
cIFN production upon MOG recall on pooled splenocytes of IFA (n = 3) and Env-SU (n = 3) injected EAE mice. IFN-c secretion is assessed in culture
supernatants after 24 h, 48 h and 72 h of incubation. Results are representative of two experiments.
doi:10.1371/journal.pone.0080128.g006
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observations are often made in SJL mice, in which some mice
develop a very mild, barely detectable first wave of EAE (with only
a single day of clinically detectable paralysis, with a score of 0.5),
but go on to develop a significant relapse 10–15 days later, with a
score of 2.0 or greater [6,9]. The body weight changes and
histological analysis suggest that in addition to the mice with clear,
clinical signs of EAE, additional mice developed CNS inflamma-
tion which was not detected in the clinical examination during the
time limits of the present study.
These in vivo observations show that the mycobacterial extract of
CFA, used in standard EAE protocol, can be replaced with the
purified recombinant MSRV-Env or Env-SU protein providing
adjuvant effects necessary for EAE induction in C57/Bl6 mice.
Importantly, the mycobacterial lysate present in CFA appears
irrelevant for studying upstream inducers of neuroinflammation in
MS since mycobacteria are not present in MS lesions. Therefore,
MSRV-Env EAE now offers a new in vivo model for further
exploring the effect of experimental disease induction by this
HERV-W protein and its potential role in MS as an upstream
inducer of neuroinflammation. This is justified by the facts that the
retroviral envelope protein from HERV-W endogenous retrovirus
family (i) has been regularly detected in MS brain lesions
[20,25,26,32], (ii) can be abnormally expressed upon HERV-W
activation by certain environmental viruses in permissive cells
[48,49] and (iii) is now shown to trigger in vivo the pathogenic
features characterizing MS lesions.
Altogether, these data suggest that MSRV-Env expression in
perivascular macrophages and/or microgliocytes [26], could be
the missing-link between triggering environmental co-factors and
the immunopathogenic cascades leading to the MS lesions and to
disease progression. Interestingly, as an endogenous retrovirus
gene, it involves a genetic interface between various infectious
agents and the pathophysiological processes activated downstream
by the engagement of TLR4 in immune cells, as well as in glial
cells [50]. The consistency of such observations with MS
pathophysiology leads to now ongoing clinical trials with a
humanized antibody neutralizing the TLR4 agonistic effects of
MSRV-Env protein in MS [51,52].
In conclusion, our study proposes that MSRV-Env could be the
common link between various triggering co-factors (e.g. infections
with an Herpesvirus such as EBV) and the immunopathogenic
cascade leading to neuroinflammatory diseases such as MS.
Although phylogenic analyses have shown that HERV-W is only
present in human and in old world monkeys (Sverdlov et al.,
2000), our data demonstrate that mice are susceptible to
neuroinflammatory disease triggered with MSRV-Env, and can
be used for studying MSRV-Env pro-inflammatory properties and
therapeutic molecules targeting this HERV-W protein.
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